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Abstract 
We recently developed a procedure to study fear incubation in which rats given 100 tone-
shock pairings over 10 days show low fear 2 days after conditioned fear training and high fear 
after 30 days. Notably, fear 2 days after 10 sessions of fear conditioning is lower than fear seen 
2 days after a single session of fear conditioning, suggesting that fear is suppressed.  Here, we 
investigate the potential role of CB1 receptor activation by endocannabinoids in this fear 
suppression. We gave rats 10 days of fear conditioning and then gave systemic injections of the 
CB1 receptor antagonist SR141716 before a conditioned fear test conducted 2 days later under 
extinction conditions. A second test was conducted without any injections on the following day 
(3 days post-training) to examine fear extinction retention. SR141716 injections did not increase 
fear expression 2 days after extended fear conditioning or affect within-session extinction, but 
impaired retention of between-session fear extinction in the day 3 test. These data suggest that 
CB1 receptor activation is not suppressing fear soon after extended fear conditioning in the fear 
incubation task. The data also add to an existing literature on the effects of CB1 receptors in 
extinction of conditioned fear.  
Keywords: Fear incubation, fear conditioning, PTSD, CB1, endocannabinoids, rimonabant  
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Fear conditioning involves pairing an initially neutral cue (e.g. a tone or distinctive place) with an 
aversive stimulus (e.g. footshock). After this training, the cue gains the ability to elicit an aversive reaction. 
In some cases, fear increases after the cessation of fear conditioning across an interval free of further stress 
or fear conditioning trials, a phenomenon called “fear incubation” (McAllister & McAllister, 1967) [footnote 
1]. There are reports of increases in fear expression across the 24-h following fear training in both humans 
and laboratory animals (Diven, 1937; Golin, 1961; McMichael, 1966; Houston et al., 1999; Balogh et al., 2002). 
However, in most cases, there are no changes in fear over days or weeks after the first 24-h period (Gleitman 
& Holmes, 1967; Hendersen, 1978; Gale et al., 2004). Due to the difficulty in reliably observing a growth of 
fear over time beyond the first 24-h after fear conditioning, the mechanisms of fear incubation are not well 
understood. 
We recently developed a model in which fear, as measured with conditioned suppression of lever-
pressing and conditioned freezing, is low 2 days after extended fear conditioning (10 sessions of tone-
footshock pairings) and increased significantly 1 month after the end of conditioning (Pickens et al., 2009b; 
Pickens et al., 2010; Pickens et al., 2013). If only one day of fear conditioning was given, conditioned fear 
was high 2 days later and did not increase further across the subsequent month (Pickens et al., 2009b).  In 
our initial pharmacological investigation, we studied the role of neuropeptide Y (NPY), an 
anxiolytic neuropeptide involved in anxiety and stress responses (Heilig et al., 1994), in fear 
incubation.  We found that ventricular injections of neuropeptide Y (NPY) reduced both 
incubated fear (10 days of fear training, test after 1 month) and non-incubated fear (1 day of fear 
training, test after 2 days) (Pickens et al., 2009a).  However blockade of the Y1 receptor 
involved in the anxiolytic effects of NPY did not increase the low pre-incubated fear seen 2 days 
after extended (10 day) fear conditioning, suggesting that endogenous NPY neurotransmission 
is not responsible for the low fear seen soon after extended training. 
Here, we examine whether endogenous cannabinoid neurotransmission is responsible for 
the low pre-incubated fear observed 2 days after extended fear conditioning, or has an effect on 
extinction of this low pre-incubated fear.  Moderate levels of CB1 activation have anti-anxiety 
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effects (Viveros et al., 2005; Ruehle et al., 2012). Also, CB1 receptor antagonist injections block 
within-session extinction in mice (Marsicano et al., 2002; Plendl & Wotjak, 2010) and between-
session extinction retention in mice and rats (Marsicano et al., 2002; Chhatwal et al., 2005).  
CB1 knockout mice are impaired at within-session extinction (Marsicano et al., 2002; Cannich et 
al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; Plendl & Wotjak, 2010; Kamprath et al., 
2011) and between session-extinction retention (Marsicano et al., 2002; Cannich et al., 2004; 
Kamprath et al., 2011).  Because there were already several experiments that showed effects of 
SR141716 on the extinction of fear following limited fear conditioning (1-2 sessions), we wanted to 
investigate the effects of SR141716 on conditioned fear after extended fear conditioning. The fear incubation 
procedure, with its low pre-incubated fear that is not seen after other fear conditioning procedures, provides 
a novel opportunity to investigate the effects of CB1 receptors. This approach can investigate whether 
endocannabinoids acting at CB1 receptors cause a suppression of fear expression (as seen in the low pre-
incubated fear test), in addition to the within- and between-session extinction that is often measured using 
other procedures. We gave rats 10 days of fear conditioning and 2 days later tested whether 
injections of the CB1 receptor antagonist/inverse agonist SR141716 (rimonabant) would 
increase low pre-incubated conditioned fear or slow within-session extinction.  We also tested 
the rats the following day (day 3) without pre-test injections to see if SR141716 would affect 
between-session extinction retention.  
 
Methods 
All procedures followed the guidelines outlined in the “Principles of Laboratory Animal 
Care” (NIH publication no. 85-23) and were approved by the local Animal Care and Use 
Committee.  Male Long-Evans rats (total n=31, Charles River, Raleigh, NC, 295-370 g on the 
first day of food restriction) were individually housed in a colony room under a reverse 12-h:12-h 
light-dark cycle with lights off at 9 am.  The rats were weighed and then given 4 g/d of food until 
they reached 85% of their weight on day 1, and then received 18-20 g/d thereafter.  The fear 
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incubation effect is most apparent under food-restriction. Fear incubation is seen at food-restriction 
conditions both milder and more severe than the ones used in this experiment, and is not dependent on the 
particular food restriction conditions.  However, the strongest incubation effect was seen under the 
conditions used here where the rats are restricted to 85% of their initial weights and then allowed to grow 
(Pickens et al., 2009b; Pickens et al., 2010).  Experiments were conducted in 12 self-administration 
chambers (Med Associates, St Albans, VT).  Each chamber had two levers 9 cm above the 
floor, but only one lever ("active," retractable lever) activated the pellet dispenser, delivering 45-
mg food pellets (# F00021, 5.5% fat, 60% carbohydrate, 4.5% fiber; Bioserv, Frenchtown, NJ).  
The chambers’ grid floors were connected to electric shock generators. 
Drugs 
SR141716 ([N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide) (NIMH Chemical Synthesis and Drug Supply Program) was prepared 
fresh before testing.  SR141716 was dissolved in 5% ethanol and 5% Tween-80 in sterile water 
and was injected (0, 1 and 3 mg/kg, s.c.) 30 min before testing.  Doses were chosen based on 
previous studies showing effects on reinstatement of alcohol, nicotine and oral-sucrose seeking 
(Cippitelli et al., 2005; De Vries et al., 2005) in rats. 
Procedures 
We used a fear incubation protocol consisting of 7 phases (Fig. 1A): magazine training 
(1 session), lever press training (5 sessions), conditioned fear training (10 sessions), incubation 
period (2 days or 30 days), lever reacquisition (1 session), cue-induced fear test (1 session), 
and extinction test (1 session).  Rats were trained during the dark cycle.  Sessions began with 
extension of the active lever and illumination of a red houselight.  Rats were weighed and fed 
after the daily sessions. 
Food/lever training  
Eight-nine days after the initial day of food restriction, the rats were given 60-min 
magazine training (pellet delivery every 125 s).  The following day, 2 sessions on a fixed-
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interval-1 (FI-1) reinforcement schedule (lever-presses could earn a pellet each sec) were run 2-
4 h apart.  These sessions ended when rats received 50 pellets (up to 1 h).  The rats were then 
given one 90-min session in which pellets were earned under a variable-interval-30 (VI-30) 
reinforcement schedule (pellet availability for lever-presses ranging from 1 to 59 sec), and 2 
daily 90-min sessions on a VI-60 schedule (pellet availability ranging from 1 to 119 sec).  Rats 
were maintained on the VI-60 schedule for the rest of the experiment. 
 
Conditioned fear training 
Conditioned fear training occurred over ten 90-min sessions during which the rats were 
given ten 30-sec tones (2900 Hz, 20 dB above background), ranging from 3 to 14 min apart and 
co-terminating with an electric shock (0.5-sec, 0.5-mA, scrambled, shock intensity adjusted for 
inter-chamber variability) while earning pellets on a VI-60 schedule.  Conditioned inhibition of 
lever-pressing for food pellets was our measure of fear (Estes & Skinner, 1941; Hunt & Brady, 
1951).  Lever-presses were recorded during the 30-sec prior to tone presentation (Precue) and 
during the 30-sec tone presentation (Cue), and were converted into a suppression ratio:  
Suppression ratio = ((Precue-Cue)/(Precue+Cue)).  The suppression ratio normalizes lever-
pressing during the tone for baseline precue responding (Annau & Kamin, 1961; Armony et al., 
1997).  A value of 1 indicates total conditioned suppression of lever-pressing during tone 
presentation (high fear).  A value of 0 reflects no lever-press suppression during tone 
presentation (no fear).  The rats assigned to the different treatments (Incubation Day and Dose) 
were matched for their precue lever press rates and suppression ratios during training.   
Cue-induced fear and extinction retention tests 
Two days after conditioned fear training, we determined the effects of acute injections of 
the CB1 receptor antagonist, SR141716 prior to cue-induced fear tests.  Rats were divided into 
3 groups (n=7-8/group) that received either vehicle or SR141716 (1 or 3 mg/kg, s.c.).  
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One day after the conditioned fear training phase, lever-pressing was re-stabilized in a 
90-min baseline session with no tones or shocks during the lever reacquisition phase.  The 
following day (day 2 post-training), conditioned fear to the tone was tested by presenting four 
30-sec tones, without shock, over 35 min.  The first tone occurred after 6.5 min and subsequent 
tones occurred after inter-trial intervals of 4, 7, and 11 min.  Rats received injections of vehicle 
or SR141716 (1 or 3 mg/kg, s.c) 30 min before the start of the test session.  On the following 
day (day 3 post-training), the rats received a second conditioned fear test without any prior 
injections, to test for retention of conditioned fear extinction.  The injections before the day 2 test 
were intended to allow for a test of the effects of SR141716 on retrieval and expression of the fear memory 
and within-session extinction on day 2. There were no injections before the day 3 retest, to allow for an 
examination of how SR141716 affected extinction learning or consolidation the previous day without any 
effect of SR141716 on fear expression or retrieval during this test. We assessed both conditioned 
suppression and conditioned freezing during the initial cued fear test (Test) and extinction 
retention test (Retest).  Multiple measures were used in order to ensure that any pattern of data seen was 
not dependent upon the use of a single fear measure. Freezing, defined as immobility except for 
movement related to breathing (Fanselow, 1980), was measured during the precue and cue 
periods every 2 sec (according to a metronome) by a blind rater previously shown to have inter-
rater reliability of r=0.92 with another blind rater.  The suppression ratios and conditioned 
freezing across the 4 extinction trials were used as our measure of conditioned fear in order to 
assess the strength of the incubated fear response over repeated trials. 
An additional group of rats (n=9) was tested for conditioned fear 30-31 days after fear 
conditioning training.  These rats were weighed and fed daily during the incubation interval, with 
continuation of the food-restriction conditions. The experimental test conditions were the same 
as the ones described above with a lever reacquisition session occurring on day 29 post-
training, and two cue-induced fear tests occurring on day 30 and day 31 post-training, 
respectively.  On the initial conditioned fear test, rats received vehicle injections 30 min before 
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the start of the test session on day 30.  The aim of this experimental group was to verify that, 
under our experimental conditions, the fear levels measured on day 2 and 3 post-training were 
lower (low pre-incubated fear) compared to the ones measure at a 1 month incubation interval.  
Statistical analyses 
All data were analyzed using Statistica 5.1 software (Tulsa, OK, USA).  Conditioned fear 
training was analyzed for the conditioned suppression measure, to ensure that all groups were 
equated before testing.  These conditioned fear training data were analyzed with a mixed-factor 
ANOVA for the course of training, with Group (4 levels: Day 2 Test-Vehicle, Day 2-1 mg/kg, Day 
2 Test-3 mg/kg, or Day 30-Vehicle) as the between-subjects factor and Training Session (the 10 
fear conditioning days) as the within-subjects factor.  The conditioned fear training data were 
also analyzed with a between-subjects factor ANOVA for the last day of training, with Group (4 
levels: Day 2 Test-Vehicle, Day 2-1 mg/kg, Day 2 Test-3 mg/kg, Day 30-Vehicle) as the 
between-subjects factor.  
Conditioned fear test data were analyzed separately for the conditioned suppression and 
conditioned freezing measures.  For each measure, conditioned fear was compared in the Day 
2 Test-Vehicle and Day 30 Test-Vehicle groups to verify that fear on day 2-3 was at low pre-
incubation levels compared to fear that increased across 1 month.  These data were analyzed 
with a mixed factor ANOVA with Incubation Day (Day 2-3 or Day 30-31) as the between-
subjects factor and Test/Retest Day (Fear Expression Test or Extinction Retention) and Test 
Trial (the 4 test trials per day) as the within-subjects factors.  For each measure, conditioned 
fear was also compared across the 3 doses of SR141716 (0, 1, and 3 mg/kg) in the groups 
tested on Day 2-3 to determine the effect of CB1 receptor blockade on low pre-incubated fear.  
These data were analyzed with a mixed factor ANOVA with SR141716 Dose (0, 1 or 3 mg/kg) 
as the between-subjects factor and Test/Retest Day (Fear Expression Test or Extinction 
Retention) and Test Trial (the 4 test trials per day) as the between-subjects factors. Significant 
effects (P<0.05) in the different ANOVAs were followed by post-hoc Tukey HSD tests. 
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Results 
Lever-press and Conditioned fear training 
Lever-press training led to a high rate of responding before the start of conditioned fear training 
(Figure 1B). Conditioned suppression increased from the first day of fear training but, in contrast to 
many of our earlier studies, did not decrease as training progressed (Fig. 1C).  This replicates 
an earlier finding that conditioned fear does not decrease across training at these feeding 
conditions (restriction to 85% of original body weight followed by 18-20 g of food per day 
(Pickens et al., 2010)).  An ANOVA of the suppression ratios during training showed a 
significant effect of Training Session (F(9,243)=3.1, p<0.01).  The groups were balanced such that 
there were no effects or interactions with Group (all F < 1) across the 10 sessions of 
conditioning or during the last conditioning session. 
Conditioned fear testing 
As previously shown (Pickens et al., 2010), conditioned fear (as measured by 
conditioned suppression of lever pressing and conditioned freezing) increased from 2 days to 1 
month after extended fear conditioning.  Systemic injections of SR141716 had no effect on fear 
expression or within-session extinction during the day 2 fear test.  The lower dose of SR141716 
tested (1 mg/kg) prevented the decrease in fear expression on the following test day (between-
session extinction retention) on day 3.   
Statistical analyses of each fear measure demonstrated the fear incubation effect.  
Conditioned suppression in rats given vehicle injections was higher on day 30-31 than on days 
2-3 (Fig. 2A).  An ANOVA of conditioned suppression in the vehicle groups, with the factors of 
Incubation Day (Day 2-3 or Day 30-31), Test/Retest Day (Fear Expression Test or Extinction 
Retention) and Test Trial (the 4 test trials per day) showed significant effects of Incubation Day 
(F(1,14)=5.4, p<0.05), Test/Retest Day (F(1,14)=34.4, p<0.01) and Test Trial (F(3,42)=15.9, p<0.01) 
and a significant interaction of Test/Retest Day X Test Trial (F(3,42)=3.6, p<0.05).  No other 
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interactions were significant (all F<1). Conditioned freezing in rats given vehicle injections was 
also higher on day 30-31 than on days 2-3 (Fig. 2B). An ANOVA of the conditioned freezing in 
the vehicle groups, with the factors of Incubation Day (Day 2-3 or Day 30-31), Test/Retest Day 
(Fear Expression Test or Extinction Retention) and Test Trial (the 4 test trials per day) showed 
significant effects of  Incubation Day (F(1,14)=5.3, p<0.05), Test/Retest Day (F(1,14)=12.3, p<0.01) 
and Test Trial (F(3,42)=7.9, p<0.01).  No other interaction were significant (all p>0.05). 
The lower dose of SR141716 (1 mg/kg) blocked the retention of extinction of conditioned 
suppression at 2-3 days after extended fear training, but neither 1 mg/kg nor 3 mg/kg SR141716 
had an effect on fear expression at this time (Fig. 3A).  An ANOVA of conditioned suppression 
during the cue with the factors of SR141716 Dose (0, 1 or 3 mg/kg), Test/Retest Day (Fear 
Expression Test or Extinction Retention) and Test Trial (the 4 test trials per day) revealed 
significant effects of Test/Retest Day (F(1,19)=21.7, p<0.01), Test Trial (F(3,57)=16.2, p<0.01) and 
significant interactions of SR141716 Dose X Test/Retest Day (F(2,19)=3.7, p<0.05) and 
Test/Retest Day X Test Trial (F(3,57)=5.3, p<0.01).  No other main effects or interactions were 
significant (all F<1).  The significant SR141716 Dose X Test/Retest Day interaction was 
followed up by post-hoc Tukey HSD tests.  This analysis demonstrated that there were no 
differences between the groups given the different SR141716 doses in the day 2 fear test, but 
that the group treated with 1 mg/kg of SR141716 exhibited significantly higher conditioned 
suppression than the vehicle group in the extinction retention test the following day.  Precue 
lever press rates in the three groups are shown in Table 1.  An ANOVA of precue lever pressing 
with the factors of SR141716 Dose (0, 1 or 3 mg/kg), Test/Retest Day (Fear Expression Test or 
Extinction Retention) and Test Trial (the 4 test trials per day) showed a significant effect of Test 
Trial (F(3,57)=5.4, p<0.01).  No other effects or interactions were significant (all F<1).   
The lower dose of SR141716 blocked the retention of extinction of conditioned freezing 
at 2-3 days after extended fear training, but neither SR141716 dose tested (1 and 3 mg/kg) had 
an effect on fear expression at this time (Fig. 3B).  An ANOVA of conditioned freezing during 
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the cue with the factors of SR141716 Dose (0, 1 or 3 mg/kg), Test/Retest Day (Fear Expression 
Test or Extinction Retention) and Test Trial (the 4 test trials per day) revealed significant effects 
of Test/Retest Day (F(1,19)=12.0, p<0.01), Test Trial (F(3,57)=13.9, p<0.01) and a significant 
interaction of SR141716 Dose X Test/Retest Day (F(2,19)=3.6, p<0.05).  No other main effects or 
interactions were significant (all p>0.05).  The significant SR141716 Dose X Test/Retest Day 
interaction was followed up by Tukey HSD tests.  This analysis demonstrated that there were no 
differences between the groups given the different SR141716 doses in the fear test, but that the 
group treated with 1 mg/kg of SR141716 exhibited significantly higher conditioned freezing than 
the vehicle group in the extinction retention test the following day.  Precue conditioned freezing 
in the three groups is shown in Table 1.  An ANOVA of precue freezing with the factors of 
SR141716 Dose (0, 1 or 3 mg/kg), Test/Retest Day (Fear Expression Test or Extinction 
Retention) and Test Trial (the 4 test trials per day) revealed no significant effects or interactions 
(all p>0.05).   
 
Discussion 
We found that the fear response, as measured by conditioned suppression of lever 
pressing and conditioned freezing during exposure to a discrete tone cue previously paired with 
shock, was higher 1 month after 10 sessions of fear training than after 2 days.  These findings 
replicate those from our recent studies (Pickens et al., 2009a; Pickens et al., 2009b; Pickens et 
al., 2010) that demonstrated that conditioned fear following an extended training period 
incubates over time (also see Millenson & Dent (1971) and Rosas & Alonso (1997) for related findings).  
Because previous findings demonstrated that fear is lower 2 days after extended fear training 
(10 sessions) than 2 days after limited fear conditioning (1 session), this procedure provides an 
opportunity to determine whether endocannabinoids acting at CB1 receptors can suppress fear in the 
absence of extinction, which is not possible with the high fear seen soon after limited fear conditioning. We 
investigated whether endocannabinoids acting at CB1 receptors are suppressing the fear 
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response 2 days after extended fear conditioning.  We found no evidence that blocking CB1 
receptors “unmasks” suppressed fear expression 2 days after extended fear conditioning.  We 
also found no evidence that blocking CB1 receptors prevents within-session fear extinction 
measured two days post-training, although the lower dose of the CB1 receptor antagonist (1 
mg/kg, s.c.) did impair between-session retention of the extinction assessed on the following 
day (day 3 post-training). Notably, these effects were not limited to a single fear measure, as this pattern 
of data was consistent between two measures of conditioned fear (conditioned freezing and conditioned 
suppression of lever pressing). 
Technical considerations 
 There are several methodological issues that should be considered before concluding 
that CB1 receptor blockade impaired retention of extinction.  These methodological 
considerations include 1) the effects that SR141716 systemic administration may have on 
locomotor activity or motivation to respond for food, 2) the possibility that SR141716 was still 
present during the day 3 test, and 3) the possible causes for the higher dose of SR141716 
tested (3 mg/kg, s.c.) being ineffective at affecting the fear response under our experimental 
conditions.   
One important factor to consider is whether SR141716 may have caused changes in 
baseline locomotor activity or in motivation to earn food by lever pressing, since conditioned 
suppression of lever pressing would be affected by changes in baseline lever pressing. 
Although previous studies have found that SR141716 does not affect locomotor activity in the 1-
5 mg/kg i.p. range (Freedland et al., 2000; McLaughlin et al., 2003), SR141716 can affect lever 
pressing for food under fixed-ratio schedules at these doses (Freedland et al., 2000; McLaughlin 
et al., 2003; De Vry & Jentzsch, 2004).  However, as can be seen in Table 1, there were no 
significant changes in baseline lever-press rates or precue freezing in the tests.  Therefore, it is 
highly unlikely that SR141716-induced changes in locomotor activity or SR141716-induced changes in 
motivation for the food caused by food-restriction are responsible for the changes in conditioned 
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freezing or conditioned suppression of lever-pressing seen in this experiment.  In addition, 
because lever-presses in our task earned food pellets, the fact that we saw the same pattern of results in our 
lever-press-dependent and lever-press-independent fear measures (conditioned suppression of lever 
pressing and conditioned freezing, respectively) suggests that changes in the motivation for food are not 
responsible for the effects of SR141716 in our task. 
 A second issue that should be addressed is whether the impairment of extinction 
retention seen on day 3 test after injections of SR14716 (1 mg/kg, s.c.) prior day 2 test, is due to 
some effects on extinction learning or consolidation, or whether some residual SR1419716 still 
present on day 3 may interfere with the fear response on that day.  Effects of residual 
SR141716 on behavior in the day 3 test seem unlikely for several reasons.  First, experiments 
examining the effects of SR141716 on antagonizing the behavioral effects of Δ9-THC on drug 
discrimination and lever pressing for food have estimated its functional half-life to be between 
~100 and 130 minutes depending on the Δ9-THC dose (Jarbe et al., 2010).  Furthermore, an 
experiment looking at the effects of SR141716 on lever-pressing for food in the absence of Δ9-
THC estimated its half-life to be ~15 hours (McLaughlin et al., 2003).  In both cases, the 
SR141716 half-life is less than the 24.5 hour interval between the SR141716 injection and the 
day 3 test.  Second, the SR141716 injection had no effect on fear expression or within-session 
extinction in the day 2 test.  Thus, it is unlikely that the effects of SR141716 in the day 3 test 
were caused by residual SR141716 acutely affecting fear expression, retrieval of the fear memory, 
or within-session extinction during the day 3 test.   
The effect of the 1 mg/kg, but not the 3 mg/kg dose in our study was surprising.  
However, it is possible that the higher 3 mg/kg dose tested may have caused off-target effects 
(Pertwee et al., 2010).  These potential effects may be explained by a higher bioavailability of 
SR141716 due to the subcutaneous route of administration or the potential decreased uptake 
into adipose tissue of the highly lipophilic SR141716 (Katoch-Rouse et al., 2003) in food 
restricted animals with lower body fat. 
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No unmasking of fear by blocking CB1 receptors 
In previous studies, we have shown that a single session of fear conditioning, using the 
same parameters as in the extended fear training used to demonstrate fear incubation, causes 
high fear in a test 2 days later (Pickens et al., 2009a; Pickens et al., 2009b).  However, after 
extended fear conditioning, fear is relatively low.  This is in accord with previous literature that 
showed that, with relatively mild footshock parameters (0.5 mA, but not stronger), there is a non-monotonic 
fear acquisition curve such that extended training causes lower fear expression than limited training  (Annau 
& Kamin, 1961; Millenson & Hendry, 1967). It seems likely that fear is suppressed 2 days after 
extended fear training, although the neurobiological basis of this suppression of fear is 
unknown.  We previously showed that the NPY Y1 antagonist BIBO 3304 did not increase low 
pre-incubated fear (Pickens et al., 2009a), suggesting that changes in NPY signaling are not 
responsible for the low fear 2 days after extended fear training.  Another promising candidate 
was the endocannabinoids, since moderate levels of CB1 activation have anti-anxiety effects 
(Viveros et al., 2005; Ruehle et al., 2012) and can improve extinction retention (Gunduz-Cinar et 
al., 2012).  The present experiment tested whether endocannabinoids, acting at the CB1 
receptor, are suppressing fear.  However, blockade of the CB1 receptors had no effect on fear 
expression on day 2 as assayed using two different measures of conditioned fear, suggesting that CB1 
activity is not suppressing fear prior to fear incubation under these experimental conditions.  
CB1 blockade prevents between-session, not within-session, extinction 
We found evidence for an effect of CB1 receptor blockade on between-session 
extinction, but not on within-session extinction.  The effect on between-session extinction 
retention is in line with findings from other laboratories, in which CB1 receptor blockade using 
SR141716 before extinction sessions after limited fear conditioning (1-2 sessions) causes an impairment 
of fear extinction retention 24 hours later (Marsicano et al., 2002; Chhatwal et al., 2005) (but see 
(Plendl & Wotjak, 2010)).  However, several other studies have also demonstrated an effect of 
CB1 receptor antagonist or CB1 receptor genetic knockout on within-session extinction as well 
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(Marsicano et al., 2002; Cannich et al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; 
Plendl & Wotjak, 2010; Kamprath et al., 2011).  
There are several potential reasons why we did not find an effect of CB1 blockade on 
within-session extinction.  It appears that effects of CB1 receptor antagonism on within- and 
between- session extinction are dissociable, depending on the brain site affected.  Injections of 
the CB1 receptor antagonist AM251 into the central amygdala impaired within-session 
extinction, but not between-session extinction, while injections of AM251 into the basolateral 
amygdala impaired between-session extinction retention, but not within-session extinction 
(Kamprath et al., 2011).  Thus, our systemic injections may have had a greater effect on the 
basolateral amygdala than the central amygdala.  
Alternatively, our experiment had several methodological differences from previous 
experiments where CB1 blockade or knockout impaired within-session extinction, including 
differences in species, feeding conditions, and the particular method of measuring fear or shock 
intensity used in fear conditioning.  Previous experiments that have demonstrated impairments 
in within-session extinction have investigated free-fed mice with no concurrent operant task 
(Marsicano et al., 2002; Cannich et al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; 
Plendl & Wotjak, 2010; Kamprath et al., 2011).  In contrast, we investigated food-restricted rats 
performing a concurrent lever-press task, which could more closely resemble the human condition 
where people maintain relatively stable weights over time and there are goals and tasks to be accomplished 
that compete with aversive emotional reactions for control of behavior. Thus, either species differences, 
task differences, or differences in feeding conditions could account for the different effects of a 
CB1 receptor antagonist on fear extinction.  Notably, food restriction can affect the levels of 
endocannabinoids and CB1 receptors (Hanus et al., 2003; Bello et al., 2012), and this may 
change the effects of a CB1 receptor antagonist at the CB1 receptor. It is unclear which feeding 
conditions more closely resemble the human condition, although it is possible that the normal function of 
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CB1 receptors in humans maintaining stable body weights more closely resembles that seen in our food 
restricted rats.   
However, the particular shock intensity and/or the long ITIs between the extinction trials may 
also account for the lack of an effect of the CB1 receptor antagonist on within-session 
extinction.  A previous experiment in mice found that CB1 knockout mice were impaired in 
extinction of fear conditioning using 0.7- or 1.5-mA shocks, but not after conditioning using 0.5-
mA shocks or those at the mouse’s pain threshold (Kamprath et al., 2009).  Our experiment 
used 0.5-mA shocks in rats whose electrical resistance is higher.  In contrast, previous 
experiments demonstrating an effect of CB1 receptor blockade on within-session extinction 
used 0.7-mA or higher shock intensity in mice with a lower electrical resistance (Marsicano et 
al., 2002; Cannich et al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; Plendl & Wotjak, 
2010; Kamprath et al., 2011). Likewise, the previous experiments demonstrating impaired within-session 
extinction all used either a single 180-200-sec tone for extinction or individual tones with an average ITI of 80 
sec (Marsicano et al., 2002; Cannich et al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; Plendl & 
Wotjak, 2010; Kamprath et al., 2011) . In contrast, we gave individual trials during extinction and the average 
ITI between extinction trials in our test was 440 seconds. The effects of CB1 receptors in within-session 
extinction have been suggested to be due to their role in a habituation-like process (Kamprath et al., 2006). 
However, a non-associative habituation-like process has been suggested to play a larger role in within-
session extinction with massed extinction trials (shorter ITIs) (Delamater, 2004). Therefore, it is possible that 
CB1 receptors were not necessary for within-session extinction in our task because the longer ITIs in our 
task cause extinction to occur through a process other than habituation.  
Our results suggest that within- and between-session extinction are dissociable (as in Plendl & 
Wotjak, 2010, although they find the opposite pattern of CB1 receptor involvement). Our findings also 
replicate previous findings from other laboratories that between-session extinction, which represents the 
long-term memory from the extinction manipulation, is disrupted by CB1 receptor blockade (Marsicano et al., 
2002; Chhatwal et al., 2005). However, we failed to replicate findings from other laboratories that within-
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session extinction, which is often attributed to non-associative processes that occur during the non-
reinforced presentations of the CS, is also impaired by CB1 receptor blockade (Marsicano et al., 2002; 
Cannich et al., 2004; Kamprath et al., 2006; Kamprath et al., 2009; Plendl & Wotjak, 2010; Kamprath et al., 
2011). It is unclear whether this is due to longer ITIs causing within-session extinction to proceed through 
different mechanisms that are CB1 receptor-independent, due to lower shock intensities causing a fear 
memory that does not require CB1 receptors for extinction, or some other methodological difference.  
Conclusions 
 Although blockade of CB1 receptors with SR141716 prevented between-session 
extinction retention, we found no role for CB1 receptors in within-session extinction or in fear 
expression 2 days after extended fear conditioning.  To the best of our knowledge, this is the 
first demonstration of CB1 receptor blockade impairing between-session extinction of fear 
measured with conditioned suppression of lever-pressing.  These findings also suggest that 
endocannabinoids acting at the CB1 receptor are not suppressing fear and causing the low 
“pre-incubated” fear seen 2 days after extended fear conditioning.  Further work will need to be 
conducted to investigate other neural systems involved in fear extinction, habituation, or anxiety 
responses to determine the mechanism causing the suppressed fear.  
 
Footnote 1: The term fear incubation has also been used in reference to generalization of the fear to other 
cues that were never paired with shock (Siegmund & Wotjak, 2007) or increases in conditioned responding 
that occur with non-reinforced presentations of the CS (Eysenck, 1968). We believe these represent different 
phenomena than the one we are studying.  
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Table 1: 
Precue lever-pressing and conditioned freezing in the rats tested for fear on days 2-3 
Precue lever pressing (lever-press/min) 
   0 mg/kg  1 mg/kg  3 mg/kg 
Day 2 test  31.2+4.2  26.4+3.0  23.3+6.2 
Day 3 retest  30.0+4.5  27.1+3.6  22.2+4.1 
Precue conditioned freezing (% freezing) 
   0 mg/kg  1 mg/kg  3 mg/kg 
Day 2 test  1.7+1.0  5.2+3.7  5.5+3.4 
Day 3 retest  2.4+1.1  6.0+3.2  4.5+2.5 
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Figure legends 
Fig. 1. Experimental procedure: (A) Timeline of the fear incubation protocol design to study low, 
pre-incubated, fear.  (B) Acquisition of lever pressing: total lever-presses during the 90-min lever 
acquisition sessions (n=31). (C) Acquisition of fear conditioning: suppression ratios across 10 
sessions of tone-shock pairings (n=31).  * Different from Session 1, P < 0.05.  
Fig. 2. Conditioned fear was significantly higher after 1 month than 2-3 days after the end of extended fear 
conditioning (the fear incubation effect). (A) Conditioned suppression of lever-pressing. Mean (+SEM) test 
suppression ratios in rats tested 30 min after vehicle injections 2 or 30 days after the end of fear 
conditioning and retested 24 hours later without injections.  (B) Conditioned freezing. Mean (+SEM) test 
conditioned freezing in rats in rats tested 30 min after vehicle injections 2 or 30 days after the end of fear 
conditioning and retested 24 hours later without injections.  Left columns represent average behavior across 
each test session.  Right columns represent trial-by-trial data across the 4 test trials in each test. n=16, 7-9 
per incubation day.  * Different from Day 2-3, P < 0.05. 
Fig. 3. The low dose of SR141716 had no effect on fear expression, but impaired between-
session retention of conditioned fear extinction.  (A) Conditioned suppression of lever-pressing. 
Mean (+SEM) test suppression ratios in rats tested 30 min after SR141716 injections (0, 1 or 3 
mg/kg, s.c) and retested 24 hours later without SR141716 injections.  (B) Conditioned freezing. 
Mean (+SEM) test conditioned freezing in rats tested 30 min after SR141716 injections (0, 1 or 
3 mg/kg, s.c) and retested 24 hours later without SR141716 injections.  Left columns represent 
average behavior across each test session.  Right columns represent trial-by-trial data across 
the 4 test trials in each test. n=22, 7-8 per dose.  * Different from the corresponding test in the 0 
mg/kg group, P < 0.05. 
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